LAB

Standard BioTools is a broken growth story that has become a balance-sheet story. Revenue has fallen every year since 2021 ($131M → $85.3M), down another 6.2% in FY2025, and the business is deeply unprofitable: a -129% operating margin, -$110M operating loss, and -$74.3M of operating cash burn. Gross margin at ~50% is mediocre for a lab-instruments franchise, and the -$1.26B accumulated deficit is a monument to years of value destruction. On fundamentals alone this is not a quality company, and a 4.2x P/S on shrinking revenue is not obviously cheap on that lens.

What keeps this off the 'avoid' pile is the balance sheet and the price. At a $356M market cap the stock trades below its $424M of stockholders' equity, and current assets of $454M dwarf $108M of current liabilities with essentially no long-term debt ($0.3M). Even against a heavy cash burn, $121M of cash plus a large current-asset base buys real runway, and management is executing on the narrowing of losses — net loss improved 46%, operating cash flow improved 48%, and diluted EPS loss narrowed 61.5%. You are effectively paying below liquidation-ish value for an option on a restructuring working.